SITE004-0097

SITE004 (DEU) › SITE004-0097

SITE004-0097

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2025-12-18

enrolled

AEs

9

Serious

0

Dropout signal

–

Adverse events

9

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 129); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 103); relationship: NOT RELATED

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-12 (study day 102); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 90); relationship: NOT RELATED

mild assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 76); relationship: not assessed

moderate assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-09-03 (study day 63); relationship: RELATED

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 41); relationship: not assessed

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-05 (study day 34); relationship: not assessed

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-25 (study day 23); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.